Drug Profile
Research programme: adenosine A3 modulators - Gilead Sciences
Alternative Names: Adenosine A3 modulators research programme - Gilead SciencesLatest Information Update: 18 Jul 2002
Price :
$50
*
At a glance
- Originator Gilead Sciences; Nonindustrial source
- Class
- Mechanism of Action Adenosine A3 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 09 Jul 2001 This programme is still in active development
- 22 Jun 1998 New profile
- 22 Jun 1998 Preclinical development for Stroke in USA (Unknown route)